# Intarcia Therapeutics clinical trials: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Intarcia Therapeutics as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Intarcia Therapeutics: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/intarcia-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 23, 2017 | NCT03060980 | Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin | Intarcia Therapeutics | Phase 3 | Terminated | Diabetes Mellitus, Type 2 | 245 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03060980) |
| January 8, 2016 | NCT02650479 | Study of the Effects of Intravenous Exenatide on Cardiac Repolarization | Intarcia Therapeutics | Phase 1 | Completed | Healthy Adult Male and Female Volunteers | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02650479) |
| December 30, 2015 | NCT02641990 | Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects | Intarcia Therapeutics | Phase 1 | Completed | Healthy Adult Premenopausal Female Volunteers | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02641990) |
| December 30, 2015 | NCT02641899 | Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs | Intarcia Therapeutics | Phase 1 | Completed | Healthy | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02641899) |
| December 23, 2015 | NCT02638805 | Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide | Intarcia Therapeutics | Phase 3 | Completed | Diabetes Mellitus, Type 2 | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02638805) |
| December 19, 2014 | NCT02320045 | Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects | Intarcia Therapeutics | Phase 1 | Completed | Renal Insufficiency | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02320045) |
| February 25, 2013 | NCT01798264 | Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes | Intarcia Therapeutics | Phase 1 | Completed | Type 2 Diabetes | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01798264) |
| February 7, 2013 | NCT01785771 | A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c | Intarcia Therapeutics | Phase 3 | Terminated | Type 2 Diabetes | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01785771) |
| October 20, 2011 | NCT01455922 | A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes | Intarcia Therapeutics | Phase 3 | Withdrawn | Type 2 Diabetes | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01455922) |
| October 20, 2011 | NCT01455909 | A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes | Intarcia Therapeutics | Phase 3 | Withdrawn | Type 2 Diabetes | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01455909) |
| October 20, 2011 | NCT01455896 | A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650 | Intarcia Therapeutics | Phase 3 | Completed | Type 2 Diabetes | 4,156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01455896) |
| October 20, 2011 | NCT01455883 | A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes | Intarcia Therapeutics | Phase 3 | Withdrawn | Type 2 Diabetes | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01455883) |
| October 20, 2011 | NCT01455870 | A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes | Intarcia Therapeutics | Phase 3 | Completed | Type 2 Diabetes | 535 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01455870) |
| October 20, 2011 | NCT01455857 | A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes | Intarcia Therapeutics | Phase 3 | Completed | Type 2 Diabetes | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01455857) |
| July 22, 2009 | NCT00943917 | Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus | Intarcia Therapeutics | Phase 2 | Completed | Type 2 Diabetes | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00943917) |
| August 23, 2007 | NCT00519792 | Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment | Intarcia Therapeutics | Phase 1 | Completed | Chronic Hepatitis C | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00519792) |
| December 21, 2005 | NCT00267553 | Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer | Intarcia Therapeutics | Phase 3 | Terminated | Breast Neoplasms, Neoplasms, Hormone-Dependent | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00267553) |
| November 23, 2004 | NCT00097344 | The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | Intarcia Therapeutics | Phase 3 | Terminated | Breast Neoplasms, Neoplasms, Hormone-Dependent | 842 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00097344) |
| November 18, 2004 | NCT00097045 | Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C | Intarcia Therapeutics | Phase 2 | Completed | Hepatitis C | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00097045) |
| May 5, 2004 | NCT00010322 | Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer | Intarcia Therapeutics | Phase 3 | Terminated | Breast Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00010322) |
| August 27, 2002 | NCT00044291 | Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | Intarcia Therapeutics | Phase 3 | Completed | Breast Neoplasms, Neoplasms, Hormone-dependent | 865 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00044291) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 2 | 2 |
| Phase 3 | 13 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Terminated | 5 |
| Withdrawn | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 11 |
| Breast Neoplasms | 4 |
| Neoplasms, Hormone-Dependent | 3 |
| Carcinoma, Ductal, Breast | 3 |
| Carcinoma, Lobular | 3 |
| Hepatitis C | 2 |
| Hepatitis C, Chronic | 1 |
| Recurrence | 1 |
| Renal Insufficiency | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Stone and masonry companies in the United States](https://specstream.ai/data/businesses/stone-and-masonry-companies/united-states)
- [Polynesian restaurants in the United States](https://specstream.ai/data/businesses/polynesian-restaurants/united-states)
- [Maternity centers in the United States](https://specstream.ai/data/businesses/maternity-centers/united-states)
- [Health food restaurants in the United States](https://specstream.ai/data/businesses/health-food-restaurants/united-states)
- [Eastern European restaurants in the United States](https://specstream.ai/data/businesses/eastern-european-restaurants/united-states)
- [Business management services in the United States](https://specstream.ai/data/businesses/business-management-services/united-states)
